Loading...Loading...Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company’s unique business model centered around royalties and healthcare assets.The company receives royalties from GSK plc GSK for popular asthma and COPD products, including Relvar/Breo and Anoro, with combined sales of over $2 billion in 2023. “We believe their manufacturing complexity provides further protection from potential competitors,” Cantor analyst writes.Cantor projects around $1.1 billion of 5-year p ...

GSK (GSK) announced that the FDA has approved the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy for adults aged 50-59 who are at increased risk of RSV disease.  Arexvy is currently approved in the United States, Europe, Japan and several other countries in adults aged 60 and more for the prevention of lower respiratory tract disease (LRTD) caused by RSV. With the latest approval, Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.In the United St ...

The Food and Drug Administration on Friday expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the potentially lethal virus. The shot, called Arexvy, is the first vaccine cleared by the FDA to protect that population from RSV. The agency first approved GSK's jab in May 2023 for patients 60 and above, who are more vulnerable to severe cases of the virus. RSV causes thousands of hospitalizations and deaths among sen ...

Many investors expected today's move in GlaxoSmithKline (NYSE:GSK), with shares of GSK stock plunging more than 8% in early afternoon trading. That's because, on Friday, a Delaware judge ruled that expert witnesses would be allowed to testify in court that the company's discontinued Zantac heartburn medication may have caused cancer. This ruling will allow 70,000 lawsuits to proceed, alleging that Zantac caused cancer. Many investors in the U.K.-based drugmaker hoped the courts would dismiss this request, b ...

Key Takeaways GSK Plc American depositary receipts (ADRs) sank in intraday trading Monday after a Delaware judge allowed lawsuits to continue claiming the pharmaceutical firm's former heartburn medicine, Zantac, causes cancer. The company denies the accusations, and vows an immediate appeal. GSK said the ruling was inconsistent with one by a federal court in 2022. American depositary receipts (ADRs) of GSK Plc (GSK) tumbled in intraday trading Monday after a Delaware court ruled that lawsuits claiming the d ...

GSK (GSK) issued a statement disagreeing with the ruling by a state court in Delaware to allow jury trials for cases, which claim GSK's discontinued heartburn drug Zantac (ranitidine) causes cancer. The court's decision will allow 72,000 personal injury lawsuits filed in Delaware court to move forward to trial and expert witnesses to testify in court that Zantac may cause cancer. GSK shares declined more than 7% in pre-market trading on Monday in response to the legal setback. If the claims are proved in co ...

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. LONDON — Shares of British pharmaceuticals giant GSK plunged 9% Monday, after a U.S. court ruled that scientific evidence could be presented in a stack of lawsuits relating to the discontinued heartburn drug Zantac. The Delaware State Court late on Friday ruled that plaintiffs' expert witnesses could testify in the roughly 75,000 cases alleging the once-popular drug ranitidine — sold under t ...

Guido Mieth GSK plc (NYSE:GSK), (OTCPK:GLAXF) is one of the largest pharmaceutical companies in Europe, with one of the leading positions in global markets for HIV drugs, and it also has an extensive portfolio of FDA-approved vaccines. Investment thesis Since the beginning of 2024, the company's share price has increased by more than 22% and continues to trade well above the 200 EMA, reflecting the optimism of financial market participants about GSK's business prospects even despite the impact of some of th ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scor ...

GSK’s (GSK) two-phase III studies, which evaluated depemokimab for treating severe asthma characterized by type II inflammation, met their primary endpoints.The primary endpoints of the SWIFT-1 and SWIFT-2 studies were a reduction in the annualized rate of clinically significant exacerbations (asthma attacks) over 52 weeks. Positive headline data from the SWIFT-1 and SWIFT-2 studies showed that treatment with depemokimab resulted in statistically significant and clinically meaningful reductions in exacerbat ...